Transforming Cardiotoxicity Detection in Cancer Therapies: The Promise of MicroRNAs as Precision Biomarkers
Isabel Moscoso(Universidade de Santiago de Compostela), Ricardo Lage(Centro de Investigación en Red en Enfermedades Cardiovasculares), José Ramón González‐Juanatey(Centro de Investigación en Red en Enfermedades Cardiovasculares), María Amparo Martínez-Monzonis(Centro de Investigación en Red en Enfermedades Cardiovasculares), Marta E. Vilar-Sánchez(Universidade de Santiago de Compostela), Moisés Rodríguez‐Mañero(Complejo Hospitalario Universitario de Santiago), Valentina Serrano-Cruz(Universidade de Santiago de Compostela), Milagros Pedreira, María Cebro-Márquez(Universidade de Santiago de Compostela), Iria Vidal-Abeijón(Universidade de Santiago de Compostela), Pilar Mazón‐Ramos(Universidade de Santiago de Compostela)
Cited by 6
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Periodontitis and cardiovascular diseases: Consensus report
|Journal Of Clinical Periodontology|2020|1.5k
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry
|European Heart Journal|2020|282
Periodontitis and Cardiovascular Diseases. Consensus Report
|Global Heart|2020|274
Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
|European Journal of Heart Failure|2023|187